# Kronos Bio (stock symbol: KRON) Logo in transparent PNG and SVG formats

## Kronos Bio Logo large

### Kronos Bio Logo large Download PNG (13.07 KB)

![Kronos Bio Logo large Download PNG (13.07 KB)](/img/orig/KRON_BIG-56d85b0f.png)

### Kronos Bio Logo large Download SVG (3.06 KB)

![Kronos Bio Logo large Download SVG (3.06 KB)](/img/orig/KRON_BIG-37a2c1f0.svg)

## Kronos Bio Logo icon format

### Kronos Bio Logo icon format Download PNG (70.16 KB)

![Kronos Bio Logo icon format Download PNG (70.16 KB)](/img/orig/KRON-865facf3.png)

### Kronos Bio Logo icon format Download SVG (754 Bytes)

![Kronos Bio Logo icon format Download SVG (754 Bytes)](/img/orig/KRON-3b3c042b.svg)

## Kronos Bio Logo large for dark backgrounds

### Kronos Bio Logo large for dark backgrounds Download PNG (13.02 KB)

![Kronos Bio Logo large for dark backgrounds Download PNG (13.02 KB)](/img/orig/KRON_BIG.D-22115f7a.png)

### Kronos Bio Logo large for dark backgrounds Download SVG (3.03 KB)

![Kronos Bio Logo large for dark backgrounds Download SVG (3.03 KB)](/img/orig/KRON_BIG.D-701d73be.svg)

## Kronos Bio Logo icon format for dark backgrounds

### Kronos Bio Logo icon format for dark backgrounds Download PNG (39.73 KB)

![Kronos Bio Logo icon format for dark backgrounds Download PNG (39.73 KB)](/img/orig/KRON.D-21975afc.png)

### Kronos Bio Logo icon format for dark backgrounds Download SVG (729 Bytes)

![Kronos Bio Logo icon format for dark backgrounds Download SVG (729 Bytes)](/img/orig/KRON.D-ee1c03bd.svg)

## About Kronos Bio

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.

1. Website domain: kronosbio.com
2. Employees: 101
3. Marketcap: $95.08 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
